Anavex Life Sciences Corp (AVXL)

[dia76ca]

Here is an outline of the study co-authored by Hampel and Woodcock et.al.

1. Introduction: precision pharmacology in the context of precision medicine
1.1. The road to precision pharmacology: role and contribution of time and space in systems biology for research & development programs
1.1.1. Role of time
1.1.2. Role of space
2. Homeostasis and pathway-based therapy
3. Current status of blood-based biomarkers – inflammatory and metabolomic – for preclinical Alzheimer’s disease
3.1. Inflammatory biomarkers
3.2. Metabolomic biomarkers
3.3. Biomarker perspectives
3.3.1. Biomarkers as diagnostics
3.3.2. Biomarkers as guides to therapeutics
4. Cns inflammation in Alzheimer’s disease stages biomarkers and therapeutic targets
5. Anti-amyloid beta and anti-tau therapeutic strategies
6. Rethinking and optimizing the design of clinical trials from the precision medicine perspective
6.1. The right drug
6.2. The right dose
6.3. The right patient
6.4. Conduct of precision medicine trials for Alzheimer’s disease
7. How can drug discovery programs in Alzheimer’s disease accomplish a good level of translational quality to reduce the rate of failures?
7.1. Drug discovery translational for Alzheimer’s disease therapeutics
7.2. Inadequate drug discovery process
7.3. Inadequate target engagement to test the therapeutic hypothesis
7.4. Therapeutic hypothesis is changed to accommodate the compound properties
7.5. What can we do better?
8. Perspectives
Contributors to the Alzheimer precision medicine initiative – working group (APMI–WG)


I notice Abbvie is part of this consortium. I wonder if they might be a potential partner?